Related Experiment Video
Updated: May 28, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
[Clostridium difficile infections: what is new?]
Egidia Miftode1, Daniela Leca, Olivia Dorneanu
1Universitatea de Medicină şi Farmacie "Gr. T. Popa" Iaşi, Facultatea de Medicină, Spitalul Clinic de Boli Infecţioase.
Summary
Clostridioides difficile infection (CDI) is a growing concern beyond hospitals. New treatments are being explored to combat recurrent CDI effectively and safely.
Area of Science:
- Infectious Diseases
- Microbiology
- Gastroenterology
Background:
- Clostridioides difficile is a leading cause of infectious diarrhea in healthcare settings and increasingly in the community.
- Emergence of hypervirulent strains (e.g., 027, 078/126) with enhanced toxin production, binary toxin, and fluoroquinolone resistance contributes to severe disease and recurrence.
- Standard antibiotic treatments for CDI fail to restore normal gut flora, leading to a 25% recurrence rate.
Purpose of the Study:
- To review emerging Clostridioides difficile infection (CDI) challenges, including new epidemic strains and increasing community-acquired cases.
- To explore novel therapeutic strategies for managing recurrent CDI, focusing on safety, efficacy, and minimal resistance development.
- To identify treatments that ensure high drug concentration in the colon and reduce recurrence rates.
Main Methods:
- Literature review of recent studies on Clostridioides difficile epidemiology and treatment.
- Analysis of emerging treatment modalities including new antibiotics, monoclonal antibodies, immunoglobulin, active immunization, and probiotics.
- Evaluation of treatment characteristics such as safety, systemic absorption, colon concentration, and recurrence prevention.
Main Results:
- New epidemic clones of C. difficile are associated with increased severity and resistance.
- Current antibiotic therapies are limited by high recurrence rates due to failure to restore gut microbiota.
- Promising new therapeutic approaches are under investigation to improve CDI management.
Conclusions:
- Effective management of recurrent C. difficile infection requires novel strategies beyond conventional antibiotics.
- Future therapies aim for improved safety profiles, targeted action in the colon, and reduced recurrence.
- Research is actively pursuing diverse approaches, including novel antibiotics, immunotherapies, and probiotics, to address the challenges posed by C. difficile.
Related Concept Videos
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...
01:22Healthcare Associated Infections II: Preventive Measures
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:18Dysbiosis of the Gut Microbiota
The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...